220 related articles for article (PubMed ID: 32473829)
1. Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors.
Wonn SM; Limbach KE; Pommier SJ; Ratzlaff AN; Leon EJ; McCully BH; Pommier RF
Surgery; 2021 Jan; 169(1):168-174. PubMed ID: 32473829
[TBL] [Abstract][Full Text] [Related]
2. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).
Scott AT; Breheny PJ; Keck KJ; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
Surgery; 2019 Jan; 165(1):166-175. PubMed ID: 30343949
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.
Chan DL; Dixon M; Law CHL; Koujanian S; Beyfuss KA; Singh S; Myrehaug S; Hallet J
Ann Surg Oncol; 2018 Jun; 25(6):1768-1774. PubMed ID: 29560571
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.
Norlén O; Stålberg P; Öberg K; Eriksson J; Hedberg J; Hessman O; Janson ET; Hellman P; Åkerström G
World J Surg; 2012 Jun; 36(6):1419-31. PubMed ID: 21984144
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the prognosis for N2 status in patients with small bowel neuroendocrine tumors.
Wonn SM; Ratzlaff AN; Pommier SJ; Limbach KE; Bassale S; McCully BH; Pommier RF
Am J Surg; 2021 Jun; 221(6):1135-1140. PubMed ID: 33785207
[TBL] [Abstract][Full Text] [Related]
6. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making.
Bertani E; Falconi M; Grana C; Botteri E; Chiappa A; Misitano P; Spada F; Ravizza D; Bazolli B; Fazio N
Int J Surg; 2015 Aug; 20():58-64. PubMed ID: 26074290
[TBL] [Abstract][Full Text] [Related]
7. Role of imaging in the preoperative staging of small bowel neuroendocrine tumors.
Chambers AJ; Pasieka JL; Dixon E; Rorstad O
J Am Coll Surg; 2010 Nov; 211(5):620-7. PubMed ID: 21035044
[TBL] [Abstract][Full Text] [Related]
8. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?
Maxwell JE; Sherman SK; O'Dorisio TM; Bellizzi AM; Howe JR
Surgery; 2016 Jan; 159(1):320-33. PubMed ID: 26454679
[TBL] [Abstract][Full Text] [Related]
9. Value of Surgical Cytoreduction in Patients with Small Intestinal Neuroendocrine Tumors Metastatic to the Liver and Peritoneum.
Gudmundsdottir H; Fogliati A; Grotz TE; Thiels CA; Warner SG; Smoot RL; Truty MJ; Kendrick ML; Nagorney DM; Halfdanarson TR; Cleary SP; Starlinger P
Ann Surg Oncol; 2024 Apr; ():. PubMed ID: 38689169
[TBL] [Abstract][Full Text] [Related]
10. Synchronous liver resection with cytoreductive surgery for the treatment of liver and peritoneal metastases from colon cancer: results from an Australian centre.
Alzahrani N; Ung L; Valle SJ; Liauw W; Morris DL
ANZ J Surg; 2017 Nov; 87(11):E167-E172. PubMed ID: 26178318
[TBL] [Abstract][Full Text] [Related]
11. A single institution's experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors.
Boudreaux JP; Wang YZ; Diebold AE; Frey DJ; Anthony L; Uhlhorn AP; Ryan P; Woltering EA
J Am Coll Surg; 2014 Apr; 218(4):837-44. PubMed ID: 24655881
[TBL] [Abstract][Full Text] [Related]
12. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.
Chambers AJ; Pasieka JL; Dixon E; Rorstad O
Surgery; 2008 Oct; 144(4):645-51; discussion 651-3. PubMed ID: 18847650
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of combined resection of colorectal peritoneal and liver metastases.
Downs-Canner S; Shuai Y; Ramalingam L; Pingpank JF; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
J Surg Res; 2017 Nov; 219():194-201. PubMed ID: 29078882
[TBL] [Abstract][Full Text] [Related]
14. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors.
Morgan RE; Pommier SJ; Pommier RF
Surgery; 2018 Jan; 163(1):218-225. PubMed ID: 29103583
[TBL] [Abstract][Full Text] [Related]
15. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.
Narasimhan V; Britto M; Pham T; Warrier S; Naik A; Lynch AC; Michael M; Tie J; Ramsay R; Heriot A
Dis Colon Rectum; 2019 Oct; 62(10):1195-1203. PubMed ID: 31490828
[TBL] [Abstract][Full Text] [Related]
16. Synchronous peritoneal metastases of small bowel adenocarcinoma: Insights into an underexposed clinical phenomenon.
Legué LM; Simkens GA; Creemers GM; Lemmens VEPP; de Hingh IHJT
Eur J Cancer; 2017 Dec; 87():84-91. PubMed ID: 29132061
[TBL] [Abstract][Full Text] [Related]
17. [Indications and operative procedures for neuroendocrine liver metastases].
Musholt TJ; Lang H
Chirurg; 2009 Feb; 80(2):113-21. PubMed ID: 19212693
[TBL] [Abstract][Full Text] [Related]
18. Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.
Tsilimigras DI; Ntanasis-Stathopoulos I; Kostakis ID; Moris D; Schizas D; Cloyd JM; Pawlik TM
J Gastrointest Surg; 2019 May; 23(5):1044-1054. PubMed ID: 30671800
[TBL] [Abstract][Full Text] [Related]
19. Hepatic cytoreduction for lung and renal neuroendocrine tumor metastases.
Fowler K; Li J; Pommier RF
Am J Surg; 2024 May; 231():41-45. PubMed ID: 38311516
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Simultaneous Resection of Small Bowel Neuroendocrine Tumors with Synchronous Liver Metastases.
Addeo P; Bertin JB; Imperiale A; Averous G; Terrone A; Goichot B; Bachellier P
World J Surg; 2020 Jul; 44(7):2377-2384. PubMed ID: 32179974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
